Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Background Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to develop clinically relevant and applicable criteria...

Full description

Bibliographic Details
Main Authors: Julien Mazières, Solange Peters, Andrés Cardona, Martin Reck, David Gandara, Denis Moro-Sibilot, Shirish Gadgeel, Stefanie Morris, Diana Mendus, Marcus Ballinger, Achim Rittmeyer
Format: Article
Language:English
Published: BMJ Publishing Group 2021-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/3/e001882.full

Internet

https://jitc.bmj.com/content/9/3/e001882.full

Similar Items